Trogenix Ltd, a Scottish BioTech firm devoted to modern most cancers therapies, introduced the completion of its Collection A financing, elevating €80 million, to advance its pipeline of probably healing most cancers therapies throughout a number of aggressive strong tumours.
The Collection A financing was led by IQ Capital with participation from founding investor 4BIO Capital, returning buyers Most cancers Analysis Horizons, the Mind Tumor Funding Fund, and new buyers Eli Lilly and Firm, Meltwind, LongeVC, and Calculus Capital, in addition to undisclosed non-public buyers.
Ken Macnamara, Chief Govt Officer at Trogenix, stated: “This vital funding accelerates our lead programme in glioblastoma and follow-on programme in colorectal most cancers liver metastases by means of the clinic, advances our pipeline in liver and lung cancers, and additional enhances our Odysseus platform. We’re honoured to have the help of present and new buyers who share our mission to ship breakthrough therapies and pursue cures for the 1000’s of sufferers and households dealing with devastating diagnoses annually.”
In 2025, European BioTech funding has remained strong, with capital concentrating round high-potential therapeutic platforms. Trogenix’s Collection A locations it among the many continent’s largest early-stage rounds this 12 months, alongside this morning’s Nanophoria’s €83.5 million Collection A in Italy, CHARM Therapeutics’ €68.5 million Collection B, and NUCLIDIUM’s €84 million Collection B.
The dimensions of those transactions displays continued investor dedication to European BioTech innovation, significantly the place platform applied sciences promise each scientific and business scalability.
Throughout the UK, oncology-focused ventures reminiscent of LIfT BioSciences (€12 million), Cyted Well being (over €37 million), and Enhanced Genomics (€16 million) proceed to draw substantial backing. In opposition to this backdrop, Trogenix’s spherical not solely stands out for its measurement but additionally aligns with a broader European pattern favouring precision oncology and superior gene-based therapeutics transitioning towards medical improvement.
Max Bautin, Co-founder and Managing Companion at lead investor, IQ Capital, stated: “Our outsised funding in Trogenix in in the present day’s selective funding panorama displays our confidence within the firm’s world-leading science, distinctive administration crew and a transparent roadmap for supply each within the clinic and commercially. We’re significantly excited by the potential alternatives forward throughout Trogenix’s pipeline and look ahead to our future collaboration.”
Trogenix was created in 2023 primarily based on Co-founder Professor Steve Pollard’s analysis on the College of Edinburgh – together with its UK Centre for Mammalian Artificial Biology and Institute for Regeneration and Restore – and the Most cancers Analysis UK Scotland Centre.
Utilizing confirmed AAV vectors, their proprietary Artificial Tremendous-Enhancers (SSEs) are delivered on to tumour cells with out detection. Their SSEs allow precision in gene management, successfully revealing most cancers to the physique’s immune system and killing tumour cells. For any cells escaping Trogenix’s expertise, their ‘Computer virus’ can counter recurrence, providing probably healing ‘one-and-done’ therapies for aggressive tumours.
Iain Foulkes, Chief Govt Officer at Most cancers Analysis Horizons, commented: “Trogenix’s platform expertise is a strong instance of the innovation we search to speed up. Representing our largest funding thus far, this partnership displays our dedication to advancing science with the potential to remodel most cancers therapy. As they advance into medical trials for glioblastoma, one of many hardest to deal with cancers, we’re happy to help a crew whose work may reshape therapeutic approaches and enhance outcomes for sufferers dealing with the best want.”
The funding underscores the healing potential of Trogenix’s precision genetic medicines pushed by the Firm’s Odysseus platform that identifies and targets the common vulnerabilities of strong tumours. Trogenix’s expertise delivers extremely potent mixture payloads that kill cancerous cells and stimulate the immune system while leaving surrounding wholesome tissue untouched, thereby altering the therapy paradigm for most cancers sufferers.
This funding in Trogenix additionally represents Most cancers Analysis Horizons’ largest funding to-date.
Dima Kuzmin, Co-founder and Managing Companion at founding investor, 4BIO Capital, and Chairman of Trogenix, added: “We’re proud to have supported Trogenix by means of the preliminary incubation stage and spin-out from the College of Edinburgh, and are very comfortable to proceed our help alongside this robust syndicate. It’s thrilling to see the corporate forge forward with its medical improvement to ship a pioneering portfolio of most cancers therapies to sufferers in want.”
Trogenix’s lead programme, in glioblastoma (GBM), probably the most aggressive and treatment-resistant mind cancers, is advancing towards medical trials with first affected person dosing anticipated in Q1 2026. Solely 25% of GBM sufferers survive past one 12 months and regardless of a long time of analysis and vital funding, the corporate says therapy choices stay severely restricted. The Firm’s follow-on programme is in colorectal most cancers liver metastases (CRCLM). Colorectal most cancers is the third commonest most cancers worldwide, with at the very least 25% of sufferers growing CRCLM.
Along with its lead and follow-on programmes, Trogenix can be growing its pipeline targeted on different aggressive strong cancers together with hepatocellular carcinoma and non-small cell lung carcinoma.
